由亚历山大·g·希金斯美联社作家日内瓦(美联社)——瑞士制药巨头罗氏公司周四表示,它已同意以468亿美元收购Genentech在收购瑞士企业历史上最大的。该交易,并建议通过基因泰克董事会提供每股95美元的44%的基因泰克公司罗氏并不拥有。巴塞尔协议结束漫长的企业之间的斗争,瑞士制药公司及其抗癌药物伙伴总部位于旧金山南部。罗氏公司已经增加了上周五以每股93美元。最初出价每股89美元的7月份Genentech公司董事会拒绝了。罗氏然后惊讶和华尔街的公司降低86.50美元每股出价1月30日,直接针对股东和试图绕过基因泰克董事会的反对。笼罩在谈判一直期望的研究数据的有效性Genentech的阿瓦斯丁治疗早期结肠癌。药物,基因泰克公司最畅销的产品,已经被证实可用于各种类型的乳腺癌、肺癌和结肠癌。一些分析师表示,积极研究可能会增加基因泰克公司股票的价值。罗氏表示,合并后的公司将是美国第七大制药公司的市场份额,将产生约170亿美元的年收入大约17500员工的工资在美国的制药业务。 A joint statement by both companies said the special committee of Genentech’s board of directors had approved the agreement and recommends that Genentech shareholders tender their shares in Roche’s offer. “We believe this is a fair offer for Genentech shareholders, and the committee is pleased to come to a successful conclusion of this process,” said Charles Sanders, chairman of the special committee of Genentech’s Board of Directors. “We look forward to working with Roche to complete the transaction as expeditiously as possible.” Franz B. Humer, chairman of Roche, said he was pleased that the two sides could agree. “Working together, we aim to close the transaction quickly, thus removing uncertainty for employees and allowing us to focus even more intently on innovation and long-term projects. We have tremendous respect for our colleagues at Genentech and look forward to working with them to further accelerate our search for solutions to unmet medical needs.” Roche said its Pharma commercial operations in the U.S. will be moved from Nutley, New Jersey, to Genentech’s site in South San Francisco, which will become headquarters of the combined company’s U.S. commercial operations in pharmaceuticals and operate under the Genentech name. It said this would take advantage of “the strong brand value of Genentech in the U.S. market.” Research and early development will operate as an independent center within Roche from its existing campus in South San Francisco, it said. Genentech, which calls itself the “founder of the biotechnology industry,” was created in 1976 and has worked closely with Roche for two decades.Roche acquired a 60 percent interest in Genentech in 1990. It bought out the rest of the shares nine years later, but then reduced its stake through three public offerings between July 1999 and March 2000.The size of the Roche-Genentech deal eclipses the $39 billion takeover of U.S. eye care company Alcon announced last April by Roche’s Swiss rival Novartis AG.